Control of flares and relief of urate burden with canakinumab and targeted urate-lowering therapy in tophaceous gouty arthritis

Rheumatology (Oxford). 2014 Apr;53(4):764-6. doi: 10.1093/rheumatology/ket327. Epub 2013 Oct 31.

Authors

Antonis Fanouriakis¹, Apostolos Karantanas, Eleni Fragouli, Argyro Repa, Prodromos Sidiropoulos

Affiliation

¹ Department of Rheumatology, Clinical Immunology, and Allergy, University Hospital of Heraklion, Stavrakia Voutes, 71110 Heraklion, Crete, Greece. [email protected].

PMID: 24185764
DOI: 10.1093/rheumatology/ket327

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Allopurinol / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Arthritis, Gouty / complications
Arthritis, Gouty / drug therapy*
Drug Therapy, Combination
Gout Suppressants / therapeutic use*
Humans
Hyperuricemia / complications
Hyperuricemia / drug therapy*
Male
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Gout Suppressants
canakinumab
Allopurinol